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Adipose tissue mTORC2 regulates ChREBP-driven
de novo lipogenesis and hepatic glucose
metabolism
Yuefeng Tang1, Martina Wallace2, Joan Sanchez-Gurmaches1, Wen-Yu Hsiao1, Huawei Li1, Peter L. Lee1,
Santiago Vernia1,w, Christian M. Metallo2 & David A. Guertin1
Adipose tissue de novo lipogenesis (DNL) positively inﬂuences insulin sensitivity, is reduced in
obesity, and predicts insulin resistance. Therefore, elucidating mechanisms controlling
adipose tissue DNL could lead to therapies for type 2 diabetes. Here, we report that
mechanistic target of rapamycin complex 2 (mTORC2) functions in white adipose tissue
(WAT) to control expression of the lipogenic transcription factor ChREBPb. Conditionally
deleting the essential mTORC2 subunit Rictor in mature adipocytes decreases ChREBPb
expression, which reduces DNL in WAT, and impairs hepatic insulin sensitivity.
Mechanistically, Rictor/mTORC2 promotes ChREBPb expression in part by controlling glucose
uptake, but without impairing pan-AKTsignalling. High-fat diet also rapidly decreases adipose
tissue ChREBPb expression and insulin sensitivity in wild-type mice, and does not further
exacerbate insulin resistance in adipose tissue Rictor knockout mice, implicating adipose
tissue DNL as an early target in diet-induced insulin resistance. These data suggest mTORC2
functions in WAT as part of an extra-hepatic nutrient-sensing mechanism to control glucose
homeostasis.
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I
nsulin resistance is a comorbidity of obesity, a risk factor for
type 2 diabetes (T2D), and a side effect of the immunosup-
pressant rapamycin; however, the exact mechanisms that can
lead to insulin resistance remain poorly understood. A hallmark
of T2D is failure of insulin to suppress hepatic glucose production
(HGP) leading to hyperglycemia. In hepatocytes insulin
suppresses HGP by stimulating AKT to inhibit FOXO1 (ref. 1).
Insulin also regulates HGP in mice, in which hepatic insulin
signalling is genetically ablated2–4 suggesting the existence of an
extrahepatic insulin-sensing tissue that can indirectly control
hepatic glucose output. Thus, understanding how organs
communicate to control glucose homeostasis is critical to
understanding T2D.
Traditionally adipose tissue de novo lipogenesis (DNL) was
thought to function primarily to store excess energy from
carbohydrates as more energy-dense lipid; however, unlike in
the liver, in which increased DNL often correlates with insulin
resistance, increased DNL in white adipose tissue (WAT)
correlates with insulin sensitivity5,6. Moreover, reduced DNL in
WAT is observed in obesity7,8 and can occur following prolonged
rapamycin treatment9. Recent work in rodents shows that hepatic
insulin resistance develops within a week of high-fat diet (HFD)
feeding, coincident with reduced insulin-stimulated glucose
uptake into adipose tissue, but without losing insulin-stimulated
AKT signalling in fat, and before any detectable decrease in
muscle glucose uptake, elevation of lipolysis or inﬂammation10.
This supports a model in which HFD causes selective insulin
resistance in fat and that adipose tissue glucose uptake and
DNL is linked to an extra-hepatic insulin-sensitizing signal that
may be targeted early in obesity. Deciphering the upstream
mechanisms controlling adipose tissue DNL is therefore critical to
understanding the pathogenesis of certain forms of insulin
resistance.
DNL involves taking up glucose and converting glucose-
derived citrate to acetyl-CoA (by ATP-citrate lyase/ACLY), which
is further converted to malonyl-CoA (by acetyl-CoA carboxylase/
ACC), and eventually to palmitate (by fatty acid (FA) synthase/
FASN). Palmitate is further modiﬁed by elongases and desa-
turases to produce diverse lipids. The transcriptional regulators
sterol response element-binding protein 1c (SREBP1c) and
carbohydrate response element-binding protein (ChREBP) con-
trol lipogenic gene expression11–13; however, their distinct
regulation and functional roles in adipose tissues are still being
worked out. Recently it was shown in adipose tissue that the
ChREBPa isoform functions in part by driving expression of the
N-terminally truncated ChREBPb isoform from an alternative
promoter5. ChREBPb more potently induces DNL genes and its
expression in human adipose tissue correlates with insulin
sensitivity5,8, suggesting ChREBP activity in adipose tissue may
be an important regulator of systemic glucose homeostasis.
The mechanistic target of rapamycin (mTOR) kinase is a
master regulator of metabolism whose downstream functions are
split between at least two distinct complexes. The best understood
complex, mTOR complex 1 (mTORC1) is a well-known amino
acid and growth factor sensor that promotes anabolic metabolism
by driving protein and lipid biosynthesis and suppressing
autophagy14. Its less understood sibling, mTORC2, is activated
by growth factors and is best known as the AKT hydrophobic
motif kinase (S473 in AKT1; S474 in AKT2)15. It is thought that
mTORC2 activity is essential for maximal AKT signalling to its
downstream substrates and whether AKT-independent mTORC2
pathways are critical in metabolism is not yet clear. The function
of mTORC2 in adipose tissue was previously examined using the
aP2-Cre driver to conditionally delete ﬂoxed alleles of Rictor, an
essential subunit of the complex16,17. However, several recent
studies indicate that adiponectin-Cre has greater efﬁciency and
selectivity to mature adipocytes18–21. Thus, the in vivo role of
mTORC2 in mature adipocytes remains unclear.
We recently reported that mTORC2 regulates expression of
lipogenic genes in brown adipose tissue (BAT)22 leading us to
hypothesize that mTORC2 might also regulate DNL in WAT to
control insulin sensitivity. To test this we developed a new
fat-speciﬁc mTORC2 knockout (KO) model by deleting Rictor
with adiponectin-Cre. Here, we provide evidence supporting a
model in which a primary function of adipocyte mTORC2 is to
promote Chrebpb expression and DNL. Moreover, we ﬁnd that
ablating Rictor/mTORC2 in WAT alters the lipid composition of
fat and causes severe hepatic insulin resistance. Mechanistically,
mTORC2 appears to promote Chrebpb expression and
DNL at least in part by controlling glucose uptake into
adipocytes independently of the classic AKT-AS160 pathway.
Adiponectin-Cre;Rictor conditional KO mice also exhibit reduced
fat growth on a HFD suggesting mTORC2 additionally functions
in mature adipocytes to control diet-induced adipose tissue
expansion. These data provide a new framework for exploring the
role of mTORC2 signalling in obesity and the pathogenesis of
insulin resistance.
Results
Mice lacking adipocyte Rictor have normal body growth. To
evaluate the role of mTORC2 speciﬁcally in adipose tissue, we
generated Adiponectin-cre;Rictorﬂ/ﬂ mice (herein RictorAdipoq-cre
mice). We previously conﬁrmed that adiponectin-Cre targets
mature adipocytes with high speciﬁcity and efﬁciency in our
colony23. Note that signiﬁcant differences exist between
RictorAdipoq-cre and mice in which Rictor was targeted with
aP2-cre16,17. We provide a detailed comparison in the Discussion
and in Supplementary Table 1.
Deleting Rictor with adiponectin-Cre greatly reduces RICTOR,
pAKTS473 and pAKTT450 (a growth factor insensitive mTORC2
target site) in the major visceral (that is, perigonadal or pgWAT),
subcutaneous (that is, inguinal subcutanteous or sWAT),
and brown fat (that is, interscapular BAT) depots (Fig. 1a
and Supplementary Fig. 1a) and the residual signal is from
stromal vascular fraction (SVF) cells because RICTOR and
pAKTS473/pT450 is undetectable in puriﬁed adipocytes (Fig. 1b).
In contrast, pAKTT308 is intact (Fig. 1a,b), which maintains
AKT’s ability to phosphorylate pFOXO1T24, pGSK3bS9 and
pPRAS40T246 (Fig. 1a). SVF and hepatic RICTOR levels are
normal (Fig. 1b and Supplementary Fig. 1b) conﬁrming targeting
speciﬁcity.
The body weight (Fig. 1c) and food intake (Fig. 1d) of
RictorAdipoq-cre mice consuming a standard chow diet does not
signiﬁcantly differ from controls through 20 weeks. The mass of
the major fat depots is also unaffected in both male and female
mice (Fig. 1e and Supplementary Fig. 1c) and the RictorAdipoq-cre
adipocytes appear normal by haematoxylin and eosin staining
(Fig. 1f and Supplementary Fig. 1d). Liver mass increases in
RictorAdipoq-cre mice by 18% and 13% in both males and females,
respectively (Fig. 1g and Supplementary Fig. 1e). By haematoxylin
and eosin stain the liver appears normal (Fig. 1h); however,
despite no observable difference in Oil Red O staining in the liver
between the control and RictorAdipoq-cre KO mice (Fig. 1h) there is
a measurable increase in total hepatic TAG content (Fig. 1i)
corresponding with a 16% decrease in the number of nuclei per
ﬁeld (Supplementary Fig. 1f) (indicative of increased cell size)
that may in part explain the overall increase in liver mass. Heart
mass also increases in RictorAdipoq-cre KO mice; however, kidney,
spleen, lung, thymus and muscle mass is normal (Fig. 1g and
Supplementary Fig. 1e). Total pancreas and pancreatic b-cell
mass also does not signiﬁcantly differ between KO and control
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(Fig. 1j and Supplementary Fig. 1g,h). These observations are in
contrast to those reported for RictoraP2-cre mice, which have
increased total body size because of a global increase in lean tissue
mass (including heart, kidney, spleen and pancreas but not the
liver) that is attributed to high circulating IGF1 (ref. 16). We ﬁnd
no difference in circulating IGF1 levels between RictorAdipoq-cre
mice and controls (Supplementary Fig. 1i) and conclude that in
20-week-old mice living under standard conditions, losing
adipose tissue Rictor does not affect overall fat mass or increase
whole-body lean tissue growth in this model.
Adipocyte mTORC2 controls hepatic glucose production.
Blood glucose concentrations in fasting and fed RictorAdipoq-cre
mice do not differ from controls; however, this requires
approximately threefold higher plasma insulin suggesting insulin
resistance (Fig. 2a,b). Insulin intolerance of RictorAdipoq-cre mice
was supported by insulin tolerance tests (ITTs), showing an 89%
increase in AUC (Fig. 2c and Supplementary Fig. 2a); glucose
tolerance is normal (Fig. 2d). Acutely inhibiting mTORC2 by
treating Rictor Adipoq-creERT2 mice with tamoxifen also ablates
RICTOR and pAKTS473 within 3-week of treatment
(Supplementary Fig. 2b), and this induces insulin intolerance
similar to the congenital KOs without affecting glucose tolerance
(Supplementary Fig. 2c–e) indicating insulin resistance occurs
rapidly with Rictor loss.
To better assess insulin action we performed hyperinsulinemic-
euglycemic clamps in conscious mice. The steady-state glucose
infusion rate required by RictorAdipoq-cre mice to maintain
euglycemia is 46% lower than controls indicating severe insulin
resistance (Fig. 2e). Insulin stimulated whole-body glucose uptake
and glycolysis is diminished by 31 and 32%, respectively
(Fig. 2f,g), and there is no difference in glycogen plus lipid
synthesis (Fig. 2h). Interestingly, insulin stimulated glucose
uptake into skeletal muscle—the main site of glucose
clearance—is normal (Fig. 2i), while in contrast, insulin
stimulated glucose uptake into adipose tissue decreases by 69%
in RictorAdipoq-cre mice (Fig. 2j). Basal HGP is unaltered between
both cohorts; however, insulin fails to suppress HGP in
RictorAdipoq-cre mice (Fig. 2k). The RictorAdipoq-cre mice also
express 2.2-fold more hepatic glucose 6-phosphatase (G6P)
(Fig. 2l) and they show less tolerance to a pyruvate bolus
(Supplementary Fig. 2f) consistent with increased hepatic
gluconeogenesis. Hepatic phosphoenolpyruvate carboxylase
(Pepck) is not signiﬁcantly elevated (Fig. 2l).
We also examined genes involved in hepatic lipid regulation.
Although RictorAdipoq-cre livers have elevated TAG content,
most lipogenesis genes including hepatic Srebps (Srebf1a, Srebf1c
and Srebf2), Chrebpa, and Lxra express normally in the
RictorAdipoq-cre KO livers (Supplementary Fig. 2g). We do detect
increased Chrebpb expression; however, expression of the
ChREBP targets Acly, Acc and Fasn does not signiﬁcantly differ
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Figure 1 | Growth characteristics of mice lacking Rictor in adipose tissue. (a) Western blots of the indicated total and phosphor-proteins in whole-fat
tissue lysates of Rictorﬂ/ﬂ (WT) and RictorAdipoq-Cre (KO) mice. (b) Western blots using lysates of puriﬁed adipocytes and the stromal vascular faction
(SVF) prepared from pgWAT and sWAT. (c) Body growth curves. n¼ 8. (d) Food consumption. n¼ 6. (e) Individual fat tissue mass analysis. n¼ 8–13.
(f) Representative H&E images of pgWATand sWAT. (g) Individual lean tissue mass analysis. n¼ 8–13. (h) Representative H&E images of liver and of liver
Oil Red O staining. (i) Liver TAG content. N¼6. (j) b-cell mass. N¼ 5. Data were analysed by Student’s t-test. Values are expressed as meanþ s.e.m.
*Po0.05; **Po0.01; ***Po0.001. Scale bar, 100 mM. H&E, haematoxylin and eosin.
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(Supplementary Fig. 2h) suggesting ChREBPb may have a role in
gluconeogenesis. We also ﬁnd increased expression of the TAG
synthesis genes 1-acylglycerol-3-phosphate O-acyltransferase 2
(Agpat2), whose product converts lysophosphatidic acid to
phosphatidic acid in the second step of de novo phospholipid
synthesis, and monoacylglycerol O-acyltransferase 1 (Mgat1),
whose product catalyzes the synthesis of diacylglycerols, in
RictorAdipoq-cre KO livers (Supplementary Fig. 2i); other TAG
synthesis genes are normal. The lipid uptake gene lipoprotein
lipase (Lpl) also expresses normally in RictorAdipoq-cre KO livers;
however, CD36 increases (Supplementary Fig. 2j). Among genes
that encode b-oxidation regulators, hepatic carnitine palmitoyl-
transferase 1 (Cpt1) also increases, but peroxisome proliferator-
activated receptor a (Ppara) and medium-chain acyl-CoA
dehydrogenase (Mcad) express normally (Supplementary
Fig. 2k). Collectively, these data suggest that adipose tissue
mTORC2 governs production of an adipocyte-derived signal that
regulates HGP and lipid handling.
Intracellular insulin action. As expected, insulin fails to
stimulate AKTS473 phosphorylation in RictorAdipoq-cre pgWAT
while insulin-stimulated pAKTT308 is not signiﬁcantly different
(Fig. 3a). Interestingly, activating phosphorylation of the insulin
receptor (pIRY1150/1151) is higher in the KO fat (Fig. 3a) possibly
suggesting loss of an inhibitory feedback mechanism. Moreover,
downstream insulin-stimulated AKT substrate phosphorylation
to AS160, FOXO1, GSK3b and PRAS40 does not signiﬁcantly
differ from controls (Fig. 3a) indicating normal insulin-stimu-
lated pan-AKT signalling. Overall, the sWAT gave similar
results but with a few noteworthy differences (Fig. 3b). In the
mutant sWAT pAKTT308 is more resistant to changes in insulin
levels (Fig. 3b—top) resulting in increased and decreased
phospho-AKTT308 signal relative to controls in the fasted
and insulin-stimulated state respectively (Fig. 3b—bottom).
Phospho-PRAS40 is also reduced only in the mutant sWAT;
however, AS160, FOXO1 and GSK3b phosphorylation are
normal (Fig. 3c). We conﬁrmed these ﬁndings in isolated
mature adipocytes (Fig. 3c). The fact that insulin-stimulated IR
phosphorylation and AKT signalling is largely intact in the
mutant WATs yet insulin fails to efﬁciently stimulate glucose
uptake (Fig. 2j) indicates that RictorAdipoq-cre mice have selective
adipose tissue insulin resistance.
Insulin-stimulated pAKTT308 and pAKTS473 are both attenu-
ated in RictorAdipoq-cre livers (Fig. 4a) consistent with hepatic
insulin-resistance. Curiously, in RictorAdipoq-cre muscle IR
phosphorylation is slightly higher in the unstimulated state,
while insulin-stimulated pAKTS473 is blunted (Fig. 4b) suggesting
some muscle signalling might also be altered in the mutant mice.
However, AKTT308 phosphorylation is stimulated normally in
RictorAdipoq-cre muscle (Fig. 4b), which is consistent with the
clamp data showing normal insulin-stimulated muscle glucose
clearance (Fig. 2i). These data support a model in which Rictor
loss in fat most negatively affects hepatic function. Interestingly,
primary hepatocytes isolated from RictorAdipoq-cre mice maintain
insulin resistance even when cultured ex vivo (Fig. 4c). Thus, the
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Figure 2 | Deleting Rictor in fat impairs HGP. (a) Plasma glucose level in random fed and 6 h fasted Rictorﬂ/ﬂ (WT) and RictorAdipoq-Cre (KO) mice. n¼ 6 or
8. (b) Plasma insulin level in random fed mice. n¼6. (c) Insulin tolerance test results with area under the curve to the right (ITT). n¼ 6 or 8 mice.
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male mice was evaluated by hyperinsulinemic-euglycemic clamp (n¼ 5 or 6 per group). (e) GIR. (f) Glucose turnover rate. (g) Whole-body glycolysis.
(h) Whole-body glycogen synthesis. (i) Glucose uptake in skeletal muscle (gastro). (j) Glucose uptake in adipose tissue (pgWAT). (k) HGP without or with
insulin stimulation. (l) Relative hepatic mRNA expression of the indicated gluconeogenic genes. N¼8. Data were analysed by Student’s t-test. Values are
expressed as meanþ s.e.m. *Po0.05; **Po0.01; ***Po0.001. ITT, insulin tolerance test. GIR, glucose infusion rate. GTT, glucose tolerance test.
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‘damage’ imposed on hepatic insulin signalling by Rictor loss in
fat is not easily reversible.
Altered lipid metabolism and composition in Rictor-deﬁcient fat.
Consistent with the model that DNL in WAT regulates
insulin sensitivity5,6,24 we ﬁnd that adipose tissue Rictor loss
dramatically reduces Acly, Acc and Fasn mRNA and protein
expression (Figs 1a and 5a,b). The expression of Chrebpa and
Srebf1c expression is unchanged in the mutant fat; however,
Chrebpb induction is almost completely blocked in both pgWAT
and sWAT (Fig. 5c,d). This is consistent with Chrebpb expression
driving DNL in adipocytes5. Indeed, overexpressing recombinant
ChREBPb, constitutively active ChREBP25 (ChREBP-CA), and to
a lesser extent ChREBPa rescues expression of ACLY, ACC and
FASN in Rictor-deﬁcient adipocytes supporting this notion
(Fig. 6). These data implicate adipocyte mTORC2 as a key
upstream regulator of ChREBPb-driven DNL.
Although under standard dietary conditions the adipose tissues
predominantly obtain free FAs (FFAs) from the liver and diet
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rather than DNL, we wondered whether losing Rictor in WAT
alters FA composition. The ratio of C16:0 (palmitate) to the
essential FA C18:2n6 (linoleate)—an index of DNL—is slightly
but signiﬁcantly decreased in RictorAdipoq-cre sWAT (Fig. 5e)
suggesting that despite the normal size of mutant WATs (though
trending smaller) (Fig. 1e) DNL is decreased. Moreover, C18:0
(stearate) levels decrease while C16:1n7 (palmitoleate) and
C18:1n9 (oleate) levels increase in RictorAdipoq-cre WATs
(Fig. 5f,g). These ﬁndings are noteworthy because the de novo
synthesis of palmitoleate by adipose tissue has been linked to
improved systemic insulin action26. Diets rich in oleate are also
reportedly metabolically healthy27,28. Thus, it does not appear
that a palmitoleate or oleate deﬁciency in fat is causing insulin
resistance in RictorAdipoq-cre mice.
The altered abundance of very long-chain FAs suggested
mTORC2 might additionally regulate FA elongation and/or
desaturation (Supplementary Fig. 3a). Elongation of very long-
chain FAs 6 (ElOVL6) elongates C16:0 FAs to C18:0 FAs, while
steroyl CoA desaturase (SCD1) desaturates C16:0 and C18:0 FAs
to C16:1n7 and C18:1n9, respectively. We calculated the ELOVL6
and SCD1 activity ratios by dividing their products by their
substrates (Fig. 5h,i), which indicates a decrease and increase
respectively in ELOVL6 and SCD1 activity supporting this
hypothesis. A broad survey of elongase and desaturase gene
expression further indicates that Elovl6 expression in the WAT of
chow-fed mice requires Rictor explaining the reduced C18:0/
C16:0 ratio (Fig. 5j,k and Supplementary Fig. 3b–d). In contrast,
Scd1 expression is unchanged (Fig. 5j,k). Elovl6 and Scd1 are
reportedly co-regulated ChREBP targets in the liver29. Thus, in
adipose tissue Elovl6 and Scd1 are not necessarily co-regulated
genes and the altered very long-chain FA proﬁle in the WAT of
RictorAdipoq-cre mice likely reﬂects defective elongation.
Deleting Rictor in adipose tissue mirrors the effects of HFD.
We also examined whether deleting adipose tissue Rictor affects
hepatic lipid composition. Interestingly, RictorAdipoq-cre livers
have a lipid proﬁle and ELOVL6/SCD1 ratios that parallel the
WATs but without changes in hepatic Elovl6 or Scd1 expression
(Fig. 5l–n). The livers from RictorAdipoq-cre mice also have high
levels of C14:0, C16:0, C18:1n9, C20:1n9 and C20:2 FAs with
corresponding decreases in C18:2n6 and C20:4n6 FAs (Fig. 5l).
The C16:0/C18:2n6 ratio is elevated in RictorAdipoq-cre liver
(Fig. 5e) consistent with increased DNL. But as indicated above,
most of the core hepatic lipogenic genes express normally in the
mutant mice (Supplementary Fig. 2g,h) indicating that hepatic
lipid remodelling cannot easily be explained by differences in
lipid synthesis genes. The hepatic lipid composition of Rictor-
Adipoq-cre mice could also be remodeled in part by changes in
exogenous lipid uptake as suggested by high hepatic CD36
expression (Supplementary Fig. 2j). Regardless, the hepatic lipid
proﬁle of RictorAdipoq-cre mice is remarkably similar to that
observed in livers of mice consuming a HFD despite the fact that
they are consuming normal chow30. This led us to hypothesize
that HFD and adipose tissue Rictor loss might target a common
pathway that antagonizes hepatic metabolism.
To explore this further, we compared the effects of HFD to
deleting Rictor in adipose tissue by feeding both WT and
RictorAdipoq-cre mice a HFD for 12 weeks. Interestingly,
RictorAdipoq-cre mice consuming HFD are resistant to weight gain
(Fig. 7a). This is due to a defect in adipose tissue expansion that
may partly result from a slight reduction in food consumption
(Fig. 7b,c). This is in stark contrast to RictoraP2-Cre mice, which
gain more total body weight, more pgWAT mass and more lean
tissue mass on HFD16.
Importantly, there is no signiﬁcant difference in insulin
tolerance between RictorAdipoq-cre mice consuming chow and
age-matched WT mice consuming HFD (Fig. 7e–g). Feeding WT
mice a HFD also decreases Chrebpb, Acly, Acc, Fasn and Elovl6
expression in both the pgWAT and sWAT to the same level as
that which is observed in the chow-fed RictorAdipoq-cre mice
(Fig. 7h,i). This is also reﬂected in the ACLY, ACC and
FASN protein expression patterns particularly in the sWAT
(Supplementary Fig. 4a,b). In addition, the HFD does not further
exacerbate insulin resistance in RictorAdipoq-cre mice despite these
mice developing additional hepatic steatosis (Fig. 7f,g and
Supplementary Fig. 4c). Thus, HFD and adipose tissue Rictor
loss have similar affects on gene expression and insulin sensitivity
suggesting they may target a common pathway.
To test whether the adipocyte mTORC2-DNL pathway might
be an early target of obesity-induced insulin resistance, we placed
WT mice on HFD for only 2 weeks, which induces mild insulin
resistance (Fig. 8a) and examined lipogenic gene expression. After
only 2 weeks HFD, Chrebpb, Acly, Acc and Fasn, but not Srebf1c
gene expression decreases in pgWAT and even more dramatically
in the sWAT of WT mice (Fig. 8b,c). These data are consistent
with adipose tissue mTORC2 regulating DNL and insulin
sensitivity by a mechanism that may be an early target of obesity.
A lipogenic diet improves the insulin sensitivity of knockout mice.
We next placed RictorAdipoq-cre mice on a high carbohydrate/
zero-fat diet (ZFD) for 12 weeks to maximize effects caused by a
DNL deﬁciency. RictorAdipoq-cre mice consuming a ZFD maintain
a body weight similar to controls and consume the same amount
of food (Fig. 7j,k). However, the adipose tissues are smaller
(Fig. 7l) indicating that Rictor is also more critical for fat
growth with increasing carbohydrate load. Liver mass also
increases in ZFD-fed mutants (Fig. 7m) explaining why total
body mass is unchanged relative to controls despite the decrease
in fat mass.
Interestingly, consuming a ZFD restores insulin tolerance in
RictorAdipoq-cre mice back to the level observed in the benchmark
chow-fed controls (Fig. 7g,n). This correlates with restoration of
most lipogenic genes (for example, Chrebpb, Acly, Acc and Elovl6)
back to the benchmark expression level (that is, not signiﬁcantly
different from chow-fed controls) (Fig. 7o). ZFD similarly
restores sWAT lipogenic gene expression, and for Chrebpb, Acly
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and Elovl6, to levels even higher than in the sWAT of chow-fed
controls (Fig. 7p). These increases are mirrored by increases in
ACLY, ACC and FASN protein expression (Supplementary
Fig. 5a,b). Notably, while ZFD increases lipogenic gene expression
in RictorAdipoq-cre mice to chow-fed levels, lipogenic gene
expression still remains lower relative to the ZFD-fed control
group (Fig. 7o,p). In fact, lipogenic gene expression responds
robustly in the ZFD-fed control group exempliﬁed by B11- and
28-fold Chrebpb induction in pgWAT and sWAT, respectively,
over chow-fed controls (Fig. 7o,p). Thus, even though a ZFD
improves insulin sensitivity in RictorAdipoq-cre mice (presumably
by ‘forcing’ more glucose into adipocytes), the lipogenic genes do
not respond at full capacity. Notably, ZFD also increases hepatic
lipogenic gene expression and steatosis in both the control and
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RictorAdipoq-cre mice (Supplementary Fig. 5c,d). This is consistent
with high ChREBP expression in the liver increases hepatic
lipogenic gene expression and steatosis without impairing insulin
sensitivity29. Collectively, these data support a model in which
adipose tissue mTORC2 regulates lipogenic gene expression to
produce an insulin-sensitizing signal.
Reduced glucose uptake and DNL in Rictor-deﬁcient adipocytes.
To better deﬁne the mechanism by which adipose tissue
Rictor loss alters adipocyte function, we generated primary white
preadipocytes harboring a Rictor (UBC-CREERT2) inducible-KO
(Rictor-iKO) system to examine the acute effects of inhibiting
mTORC2 on differentiation and function. When compared with
their isogenic controls, primary Rictor-iKO preadipocytes differ-
entiate normally based on PPARg, ChREBPa, C/ebpa, C/ebpb,
Ap2 and Adiponectin expression (Fig. 9a and Supplementary
Fig. 6a). In high-glucose culture medium, DNL is the primary
driver of lipid droplet formation and under these conditions
Rictor-iKO cells have smaller lipid droplets (Fig. 9b). Rictor-iKO
cells also fail to upregulate Chrebpb mRNA and Acly, Acc and
Fasn mRNA and protein (Fig. 9a,c), consistent with a DNL
deﬁciency. Moreover, both basal and insulin-stimulated glucose
uptake as well as glucose incorporation into FFAs and TAGs are
blunted in Rictor-iKO cells (Fig. 9d,e,f). As expected, RICTOR is
completely ablated in the Rictor-iKO cells by day 6 of differ-
entiation at which point AKTS473 phosphorylation is also
undetectable (Fig. 9a). In contrast, phosphorylation of AKTT308,
AS160T642 and S6KT389 (a measure of mTORC1 activity) is
unchanged relative to the isogenic control (Fig. 9a). Thus,
decreased glucose uptake and DNL is primary consequence of
Rictor loss.
GLUT4 is the major glucose transporter for insulin-stimulated
glucose uptake into adipocytes. Therefore, we next examined
whether GLUT4 regulation is defective in Rictor-deﬁcient
adipocytes. Indeed, in primary Rictor-iKO cells, Glut4 mRNA
and protein fail to induce normally during differentiation (Fig. 9g
and Supplementary Fig. 6b). Similarly, in mice consuming the
lipogenic ZFD, Glut4 is also reduced in both the sWAT and
pgWAT of RictorAdipoq-cre mice (Fig. 9h and Supplementary
Fig. 6c). Thus, in highly lipogenic conditions such as in culture
medium and a high-carbohydrate diet, Rictor is required for
maximal Glut4 gene expression. In mice consuming normal chow
however, Glut4 expression does not signiﬁcantly differ in either
depot from controls (Fig. 9h and Supplementary Fig. 6c,d).
Moreover, in HFD-fed mice Glut4 expression only decreases in
the mutant sWAT and not pgWAT (Fig. 9h and Supplementary
Fig. 6c). Thus, additional mechanism(s) of glucose regulation by
Rictor/mTORC2 in adipocytes likely exist.
We also considered other proposed modulators of insulin
resistance, such as increased lipolysis. Primary Rictor-iKO
adipocytes show no difference in basal or isoproterenol-
stimulated glycerol release (Fig. 9i) arguing against increased
lipolysis as a primary target of Rictor loss. However, pgWAT
depots resected from RictorAdipoq-cre mice show a modest increase
in basal glycerol release ex vivo; isoproterenol-stimulated glycerol
release is normal (Fig. 9j). When administered at a controlled
concentration, insulin is also ineffective at suppressing circulating
FFA levels in vivo in fasted RictorAdipoq-cre mice (Supplementary
Fig. 6e), which is consistent with insulin resistance but could
reﬂect liver dysfunction. High cholesterol is detected in the
mutants, however, circulating FFA and TAG levels are not
signiﬁcantly different between fasted control and RictorAdipoq-cre
mice possibly due to the high basal insulin levels (Supplementary
Fig. 6f–h). Moreover, RictorAdipoq-cre mice have normal hormone
sensitive lipase (HSL) levels in both depots and increased HSL
phosphorylation is not detected (Fig. 1a). Higher levels of adipose
triglyceride lipase (ATGL) associate with increased lipolysis;
however, ATGL levels are also normal in pgWAT and lower in
sWAT (Fig. 1a). Thus, defective lipolysis may contribute to
insulin resistance in the prolonged absence of Rictor/mTORC2 in
fat but it does not appear to be a primary effect.
TNF-a is undetectable in RictorAdipoq-cre mice and leptin,
resistin and PAI-1 levels are normal (Supplementary Fig. 6i–k).
We do detect reduced plasma adiponectin by B32%
(Supplementary Fig. 6l), which could contribute to insulin
resistance. However, reducing adiponectin levels reportedly has
no or only a mild defect in insulin sensitivity in chow-fed
mice31,32 suggesting this alone likely does not explain the severe
insulin resistance of RictorAdipoq-cre mice. Thus, based on the
collective in vivo and in vitro primary cell data, we propose that a
primary function of mTORC2 in adipocytes is to control ChREBP
activity by regulating glucose ﬂux, which promotes DNL and the
production of a signal(s) that promote insulin sensitivity and
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possibly adipogenesis (Fig. 10). However, prolonged Rictor/
mTORC2 loss may lead to secondary metabolic changes that
exacerbate the phenotype.
Discussion
We describe a novel model of mTORC2 in adipose tissue based
on conditional deletion of Rictor with adiponectin-Cre. There are
several phenotypic differences compared with mice in which
Rictor was targeted with aP2-Cre16,17. A detailed comparison can
be found in Supplementary Table 1. These differences likely
reﬂect the higher efﬁciency and speciﬁcity of adiponectin-
Cre18,19,21,33. For example, aP2-Cre incompletely targets
adipocytes and additionally targets adipose tissue endothelial
cells33. We ﬁnd that RictorAdipoq-Cre mice exhibit more severe
insulin resistance. In addition, RictorAdipoq-Cre gain less weight
than controls on HFD while in contrast RictoraP2-Cre mice gain
more weight on HFD. The reduced weight of RictorAdipoq-Cre
mice on HFD is largely due to a decrease in fat mass, but whether
resistance to obesity reﬂects the deﬁciency in Chrebpb expression
or DNL is not yet clear. Interestingly, it was suggested recently
that ChREBP may promote PPARg activity by controlling the
synthesis of FAs that function as PPARg ligands25. In addition,
mice lacking Fasn in adipose tissue are also resistant to HFD and
this is attributed to defective synthesis of a PPARg ligand34. Such
a ligand could act in a paracrine manner to stimulate new
adipogenesis. This requires further investigation.
Based on our results we hypothesize that adipose tissue
mTORC2 functions as part of an extra-hepatic nutrient-sensing
mechanism that relays the organism’s nutritional state to the liver
to control insulin sensitivity and glucose homeostasis (Fig. 10).
Mechanistically, our data suggest that adipocyte mTORC2
controls ChREBP activity and DNL at least in part by regulating
glucose ﬂux. Interestingly however, this mTORC2 function
appears to operate independently of AKT, the canonical
mTORC2 substrate. One possibility is that following Rictor
deletion, AKT signalling reprograms to overcome mTORC2-
dependency for some functions; however, for other AKT
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substrates the dependency for mTORC2 cannot be overcome.
An alternative possibility is that only some AKT substrates
require mTORC2-dependent hydrophobic motif phosphorylation
(S473 in AKT1; S474 in AKT2). A third possibility is that
AKT-independent mTORC2 pathways also control glucose ﬂux,
although these possibilities are not mutually exclusive.
A classic mechanism by which insulin stimulates glucose
uptake is by promoting AKT-dependent phosphorylation of
AS160, which facilitates GLUT4 translocation to the plasma
membrane35. However, AS160 phosphorylation is normal in
Rictor-deﬁcient adipocytes. Whether adipose tissue mTORC2
regulates GLUT4 translocation in vivo by other mechanism(s)
needs further investigation36. One pathway suggested by our data
is that mTORC2 might control glucose uptake by controlling
Glut4 transcription. This function of mTORC2 appears to be
most essential when the glucose load is high (for example, culture
medium or when mice are consuming ZFD/high-carbohydrate
diet). However, another mechanism(s) must exist because Glut4
expression is unchanged in the fat of RictorAdipoq1-Cre mice
consuming normal chow. One possibility based on work in
glioblastoma cells is that mTORC2 may regulate expression of
glycolytic enzymes independently of AKT; however, the
mechanism is not clear37. Nevertheless, our ﬁndings suggest
that selective mTORC2 activators may be useful anti-diabetic
drugs.
Although it is well known that in the pathogenesis of T2D
selective insulin resistance occurs in the liver38 (in which insulin
fails to suppress gluconeogenesis but continues to promote
lipogenesis) it is becoming increasingly clear that selective insulin
resistance also occurs in adipose tissue10,39–41. However, this has
been difﬁcult to understand due to lack of a genetic model.
Adipocytes lacking Rictor demonstrate selective insulin resis-
tance in that only insulin-stimulated glucose uptake and not
insulin-stimulated AKT signalling is impaired. An alternative
interpretation is that Rictor-deﬁcient adipocytes are not insulin
resistant per se, but rather have impaired glucose uptake through
an insulin/AKT-independent mechanism that indirectly
attenuates insulin-stimulated glucose ﬂux. Regardless, the
RictorAdipoq-cre mice provide a novel model of selective insulin
resistance in adipose tissue that will be useful for understanding
human selective insulin resistance.
What is the adipocyte-derived signal that communicates with
the liver? One possibility based on recent evidence is that DNL in
adipose tissue might generate a speciﬁc bioactive lipid(s) or other
factor that functions as an insulin-sensitizer6,26. Alternatively, the
signal from the fat might travel indirectly to the liver via another
tissue. For example, high basal insulin levels could promote
insulin resistance. Nevertheless, our results support an emerging
model in which adipocyte-derived signals, possibly speciﬁc de
novo synthesized lipids, are critical in regulating systemic insulin
sensitivity2,3,5–6,26,42–44. Notably, we observe that lipogenic gene
expression is rapidly downregulated following a switch to HFD
suggesting DNL may be an early target in pathogenesis of
diet-induced insulin resistance.
Is there a role for lipolysis in RictorAdipoq-cre mice? We did not
detect a lipolysis defect in primary cells suggesting altered
lipolysis may not be a primary effect of Rictor loss. However,
tissue explants from the RictorAdipoq-cre mice exhibit an increase
in glycerol release suggesting elevated lipolysis likely contributes
eventually to the in vivo RictorAdipoq-cre phenotype. Elevated
lipolysis would increase FA ﬂux to the liver, which was recently
shown to be a mechanism of impairing HGP45. Notably, a recent
reevaluation of the literature reveals that insulin resistance exists
in human obesity without elevated FFAs, and that elevated FFAs
do not necessarily cause insulin resistance46. Moreover, mice
consuming a HFD for only a few days have impaired glucose
uptake into fat and impaired HGP without altered plasma FFA
levels or reduced muscle glucose uptake, and without
inﬂammation or altered adipokine secretion10. Nevertheless, the
use of inducible KO models and in vivo metabolomics is required
to deﬁne progressively the pathogenesis of hepatic insulin
resistance in RictorAdipoq-cre mice.
A complication after organ transplantation is a syndrome
called new onset diabetes after transplantation47,48.
Immunosuppressants such as rapamcyin associate with new
onset diabetes after transplantation, and in rodent models, rapa-
mycin causes glucose intolerance and insulin resistance49–51;
however, the mechanism of rapamycin-induced metabolic disease
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to additional defects such as increased lipolysis.
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is unresolved. Rapamycin’s ability to inhibit hepatic mTORC2
may explain why it causes glucose intolerance because mice
lacking hepatic Rictor but not Raptor are glucose intolerant52;
however, hepatic Rictor-deﬁcient mice have relatively normal
insulin sensitivity indicating unknown extra-hepatic target(s)
likely contribute to rapamycin-induced metabolic syndrome. Our
genetic model suggests that targeting adipose tissue mTORC2
may be one mechanism by which rapamycin causes insulin
resistance. However, rapamycin’s effect on fat metabolism is
likely complex and fully understanding it will require carefully
analysing the acute and chronic effects of inhibiting each mTOR
complex versus rapamycin in different fat depots.
In this study, we report a novel mouse model of mTORC2 loss
selectively in adipocytes. Our results provide a new framework for
studying nutrient and growth factor sensing pathways in adipose
tissue metabolism and their role in organ-to-organ communica-
tion networks, which may have important implications for
understanding and treating human pathologies associated with
obesity and lipodystrophy.
Methods
Mice. Rictor-ﬂoxed mice were described previously53 and backcrossed with
C57BL/6 for 10 generations. Floxed mice were crossed with mice expressing either
adiponectin-Cre or adiponetin- CreERT2, or with Ubc-CreERT2 (JAX #007001) mice
to generate conditional or inducible KO models. Floxed Cre-negative mice were
used as wild-type controls. Mice were kept on a daily 12 h light/dark cycle and fed a
normal chow diet (Prolab Isopro RMH 3000) from Lab Diet ad libitum at 22 C.
All animal experiments were approved by the University of Massachusetts Medical
school animal care and use committee. For the inducible CreER models, Rictorﬂ/ﬂ
(WT) and Adiponetin-CreERT2;Rictorﬂ/ﬂ (iKO) male mice at 8 weeks old were
treated with 3mg Tamoxifen per day (i.p.) for 6 constitutive days. The age of the
mice used for all studies were 8–20 weeks old. For 2 weeks HFD experiment, mice
were randomly placed into cages with chow or HFD. No other randomization was
used while conducting experiments. No animals were excluded from any
experiments, unless they displayed obvious wounds from ﬁghting as determined
by our veterinarians
All animal studies were designed to minimize and control for confounding
variables such as mouse gender and age. Based on our previous studies, we use a
minimum of six animals per treatment group to achieve statistical power to detect
signiﬁcant differences when measuring RNA, tissue mass, body weight and blood
metabolites. Researchers were not blinded to the genotype.
Antibodies and reagents. AS160 (07-741) was purchased from Millipore. PPARg
(sc-7196) and p70 S6K (sc-9027) are from Santa Cruz. ChREBP (NB400-135) is
from Novus Biologicals. All other antibodies including Rictor (2140), Raptor
(2280), HSL (4107), ATGL (2439), PRAS40 (2691), AKT (9272), GSK3b (9315),
ACC (3676), ACLY (4332), FASN (3180), IR (3025), S473-AKT (4058), T308-AKT
(4056), T24-FoxO1 (9464), T389-S6K (234), p-IR (3024), T246-pPRAS40 (2997),
S660-pHSL (4126) and T642-pAS160 (4288), were purchased from Cell Signaling
Technologies. 4-hydroxy-tamoxifen (4-OHT) was obtained from Toronto Research
Chemicals. Rapamycin was purchased from LC Laboratories. Dexamethasone,
3-isobutyl-1-methylxanthine (IBMX), Tamoxifen, and all other reagents were from
Sigma-Aldrich.
Metabolic Studies. Hyperinsulinemic-euglycemic clamps were performed
following an overnight fast, a 2-h hyperinsulinemic (insulin at 150mUkg 1 body
weight priming followed by 2.5mUkg 1min 1)-euglycemic clamp was con-
ducted in awake mice using (3-3H)-glucose and 2-deoxy-D-(1-14C)-glucose to
assess glucose metabolism in individual tissues as described previously54. At 8
weeks of age, male mice were fed a normal chow diet (Prolab Isopro RMH 3000)
from Lab Diet, 60% HFD (D12492 Harlan Laboratories) or high-carbohydrate ZFD
(TD.03314 Harlan Laboratories) and monitored for 12 weeks. Body weight was
recorded weekly. The analysis of blood metabolites was performed by at the Joslin
Diabetes Center (Boston). For glucose tolerance tests and pyruvate tolerance tests,
mice were fasted overnight (16 h) and then administrated 2 g kg 1 of body weight
of glucose or sodium pyruvate by intraperitoneal (i.p.) injection. For insulin
tolerance tests, mice were fasted for 6 h before i.p. administration of 0.75 unit kg 1
of body weight of insulin. Blood glucose concentrations were measured before and
after the injection at the indicated time points.
Tissue metabolite extraction and gas chromatography/mass spectrometric
analysis. Polar and non-polar metabolites were extracted from tissue using
methanol/water/chloroform and derivitized as previously described55. Brieﬂy, polar
metabolites were derivatized to form methoxine-TBDMS derivatives by incubation
with 2% methoxylamine hydrochloride dissolved in pyridine at 37 C for 1 h
followed by addition of N-tert-butyldimethylsilyl-N-methyltriﬂuoroacetamide
(MTBSTFA) with 1% tert-butyldimethylchlorosilane (TBDMCS) incubated at
37 C for 30–60min. Nonpolar metabolites were saponiﬁed to FFAs and
transesteriﬁed to form FA methyl esters by incubation with 2% H2SO4 in methanol
at 50 C for 1 h. Derivatized polar samples were analysed by gas chromatography–
mass spectrometry using a DB-35MS column (30m 0.25mm i.d. 0.25 um)
installed in an Agilent 7890B gas chromatograph (GC) interfaced with an Agilent
5977A mass spectrometer. Lipid samples were analysed by gas chromatography–
mass spectrometry using a Select FAME column (100m 0.25mm i.d.) installed in
an Aglient 7890A GC interfaced with an Agilent 5975C mass spectrometer.
Tissue harvest and histology. Adipose tissue depots were carefully dissected to
avoid contamination from surrounding tissue. Samples for RNA or protein were
frozen down immediately in liquid nitrogen and then stored at  80 C for further
analysis. For histology, tissue pieces were ﬁxed by 10% formalin. Embedding,
sectioning and Hematoxylin & Eosin (HE) and PAS staining was done by the
UMass Medical School Morphology Core. For Oil Red O staining, liver samples
were embedded in OCT before sectioning and staining. For cell size measurements,
9–12 images were taken from each mouse (n¼ 3 wild-type and 3 conditional KOs).
Image J was used to measure cell size and the distribution of cell size as percentage
of total counted cells was analysed.
Western blots. Insulin stimulated signalling in each tissue was determined in mice
that were fasting for 6 h before injection with 0.75 unit kg 1 of body weight of
insulin for 15min. Each tissue was collected and frozen down immediately in liquid
nitrogen and then stored at  80 C for subsequent lysis and western blots analysis
with the indicated antibodies. Cells were lysed in a buffer containing 50mM Hepes,
pH 7.4, 40mM NaCl, 2mM EDTA, 1.5mM NaVO4, 50mM NaF, 10mM sodium
pyrophosphate, 10mM sodium b-glycerophosphate and 1% Triton X-100 typically
16 h after the cells were replenished with fresh culture medium. Tissues were
homogenized using a TissueLyser (Qiagen) in the same lysis buffer but additionally
supplemented with 0.1% SDS, 1% sodium deoxycholate. An equal amount of total
protein was loaded into acrylamide/bis-acrylamide gels and transferred to poly-
vinylidene ﬂuoride membranes for detection with the indicated antibodies. Brieﬂy,
membranes were incubated with primary antibodies (1:1,000 dilution) in 5% milk/
PBST or 5% BSA/PBST overnight. Horese radish peroxidase-conjugated secondary
antibodies (1:3,000 dilution) were given for 1 h. Western blots were developed by
enhanced chemiluminescence (PerkinElmer) and detected by X-ray ﬁlms.
Primary cell isolation and in vitro differentiation. SVF cells were isolated by
digesting the sWAT of Ubc;rictor mice in digestion buffer (NaCl (123mM), KCl
(5mM), CaCl2 (1.3mM), glucose (5mM), HEPES (100mM), P/S (1%), BSA (4%),
pH 7.4) containing collagenase A at 1.5mgml 1 (Roche). After 45min of diges-
tion, the digested tissue was ﬁltered through 100mm cell strainers (BD Falcon).
Cells were collected by centrifugation (at 300g, 5min) and cultured in DMEM
(Invitrogen) supplemented with 10% FBS and penicillin/streptomycin at 37 C. To
induce Rictor deletion, Ubc;rictor SVF cells were treated with 1 mM 4-OHT or
vehicle for 2 days when start to differentiate by adding differentiation medium
containing 2 mgml 1 dexamethasone, 100 nM insulin, 1 mM rosiglitazone and
0.5mM IBMX for 2 days, and then induced with 100 nM insulin for another 2 days
before changing back to regular medium. At different time points, the differ-
entiated adipocytes were collected for protein, mRNA or Oil-Red-O staining
analysis. For Oil Red O staining, the differentiated cells were washed three times
with PBS and ﬁxed with 10% buffered formalin at 4 C overnight. Cells were then
stained for 10min at 37 C with a ﬁltered Oil Red O solution (0.5% Oil Red O in
isopropyl alcohol), washed three times with distilled water, and visualized.
Lipogenesis assay. Isolated SVF from Ubc;rictor mouse were cultured and
differentiated into adipocytes for 7 days. The cells were then incubated in KRH
buffer supplemented with 2.5% BSA and 2 mCi per ml D-[U-14C]-glucose
(PerkinElmer) for 4.5 h with or without the presence of 150 nM insulin. The
cells were lysed with Doley’s solution (isopropyl alcohol:hexane:1N H2SO4
(v:v:v)¼ 4:1:1), and newly synthesize lipids were extracted with hexane. About 1/3
of hexane phase was used for analysing triglycerides (TAGs), and the remaining
were dried, deacylated with ethanol:water:KOH (v:v:v)¼ 20:1:1 at 80 C for an
hour, neutralized with sulfuric acid and dissolved the neutral FFAs in hexane. The
samples containing TAGs and FFAs were dried, reconstituted in scintillation ﬂuid,
and incorporation of 14C was determined by counting counts per minute (CPM).
Each condition was done in duplicate, and the experiment was repeated with three
independently isolated SVF. The incorporation was then normalized with protein
content measured by BCA protein assay kit (Bio-Rad).
2-DOG glucose uptake. Isolated SVF from Ubc;rictor mouse were cultured and
differentiated into adipocytes for 7 days. The cells were incubated in KRH buffer
supplemented with 0.5% BSA and 2mM sodium pyruvate, with or without 150 nM
insulin stimulation for 15min. [1, 2-3H] 2-deoxy-D-glucose (PerkinElmer) was
added to the samples and incubate at 37 C for 10min, and the assays were
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terminated by three-time KRH wash. The cells were lysed with 1% Triton,
dissolved in scintillation buffer and uptaken 3H was determined by counting CPM
level. The 2-DOG uptake level was normalized with protein concentration of each
sample. Each condition was done in triplicate.
Primary hepatocytes isolation and culture. Hepatocytes were isolated from mice
using a modiﬁed two-step perfusion method using Liver Perfusion Media and Liver
Digest Buffer (Invitrogen). Cells were seeded on plates (pre-coated (1 h) with
collagen I (BD Biosciences)) in DMEM plus 10% FBS, 2mM sodiumpyruvate,
1 mM dexamethasone and 100 nM insulin plus 2% penicillin/streptomycin. After
attachment (3 h), the medium was removed and the hepatocytes were incubated
(22 h) in maintenance medium (DMEM (4.5 g l 1 glucose) supplemented
with 10% FBS, 0.2% BSA, 2mM sodium pyruvate, 2% Pen/Strep, 0.1 mM
dexamethasone, 1 nM insulin) before stimulated with insulin at 100 nM insulin
for 30min.
Measurement of lipolysis of differentiated adipocytes and adipose tissue. For
measurement of lipolysis, differentiated adipocytes at day7 and pgWAT from mice
were cultured in DMEM with or without isoproterenol at 10 mM for 4 or 6 h,
respectively, before collecting medium to measure glycerol concentration
using commercial kit (Sigma). The glycerol level was normalized with protein
concentration of differentiated adipocytes and tissue mass of pgWAT.
Immunohistochemistry and b-cell mass. Parafﬁn-embedded pancreatic sections
were immunohistochemical stained with insulin. b-Cell mass of ﬁve mice per
group of each genotype was measured in insulin-stained pancreas section using
ImageJ (NIH, Bethesda, MD).
Gene expression analysis. Cells or tissues were lysated with Qiazol (Invitrogen)
and total RNA was isolated with the RNeasy kit (Invitrogen). Equal amounts of
RNA were retro-transcribed to cDNA using a high-capacity cDNA reverse
transcription kit (#4368813, Applied Biosystems). Quantitative real-time PCR was
performed in 10ml reactions using a StepOnePlus real-time PCR machine from
Applied Biosystems using SYBR Green PCR master mix (#4309156, Applied Bio-
systems) according to manufacturer instructions. Relative mRNA expression was
determined by the DCt method and Tbp expression was used as a normalization
gene in all conventional PCR with reverse transcription experiments. Primer
information is listed in (Supplementary Table 2).
Statistics. Unless otherwise stated, values given are mean±s.e.m. Two-way
analysis of variance was performed where indicated. For most experiments,
unpaired two-tailed Student’s t-tests was used to determine statistical signiﬁcance
among two groups (*Po0.05; **Po0.01;***Po0.001).
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